Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

Tadashi Toyama,Brendon L. Neuen,Min Jun,Toshiaki Ohkuma,Bruce Neal,Meg J. Jardine,Hiddo L. Heerspink,Muh Geot Wong,Toshiharu Ninomiya,Takashi Wada,Vlado Perkovic

DOI: https://doi.org/10.1111/dom.13648

2019-03-04

Diabetes, Obesity and Metabolism

Abstract:Abstract Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycemic efficacy is dependent on kidney function. We performed a systematic review and meta‐analysis to assess the efficacy and safety of SGLT2 inhibitors in patients with T2DM and CKD, defined as estimated glomerular filtration rate (eGFR) 2.